{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049880","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.497004+00:00","generated_at":"2026-05-17T00:07:33.704840+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel reports record Q3 revenue $67.5M; net income $5.1M vs loss","bullets":["Total revenue $67.5M (record Q3), MACI $55.7M (+25% YoY), Burn Care $11.8M (Epicel $10.4M, NexoBrid $1.5M).","Net income $5.1M ($0.10 diluted EPS) vs net loss $0.9M prior year; adjusted EBITDA $17.0M (25% rev) vs $10.0M (17%).","FY 2025 revenue guidance reaffirmed $272-276M; gross margin 74%, adjusted EBITDA margin 26%.","Operating cash flow $22.1M (record Q3); cash $185M, no debt; MACI Arthro >800 surgeons trained; MACI Ankle study on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049880","json":"https://secwatch.observer/filing/0001628280-25-049880.json","markdown":"https://secwatch.observer/filing/0001628280-25-049880.md","text":"https://secwatch.observer/filing/0001628280-25-049880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828025049880/0001628280-25-049880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828025049880/vcel-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:07:33.704840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}